Drugs Made In America Acquisition II (NASDAQ:DMII) Shares Down 0.2% – Should You Sell?

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII)’s share price traded down 0.2% on Wednesday . The stock traded as low as $10.08 and last traded at $10.08. Approximately 13,223 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 117,632 shares. The stock had previously closed at $10.10.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DMII shares. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Drugs Made In America Acquisition II has an average rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

The stock has a 50-day moving average price of $10.07.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DMII. Geode Capital Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter worth approximately $265,000. Virtu Financial LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at $317,000. ABC Arbitrage SA bought a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at $396,000. Deltec Asset Management LLC bought a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at $495,000. Finally, Royal Bank of Canada acquired a new position in shares of Drugs Made In America Acquisition II during the 4th quarter worth $655,000.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.